Design Therapeutics, Inc.
NASDAQ:DSGNBiotechnology
+$0.19 today
- Market cap
- $630.12M
- Beta
- 1.66
- P/E (TTM)
- -10.7
- EPS (TTM)
- -$1.13
Volume 0.29M
Average 0.74M
Returns on capital
Design Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-32.8%
avg 3.3%
ROIC
-37.1%
avg -11.5%
ROA
-30.9%
avg -342.6%
Analysis
ROA is currently the strongest return metric at -30.9% versus its period average of -342.6%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Pratik Shah | Co-Founder, President, Chief Executive Officer, Principal Financial Officer & Executive Chairperson | USD 790K | 56 | 750.00K | 1.20% |
Sean Jeffries | Chief Operating Officer | USD 698K | 46 | 375.00K | 0.60% |
Chris Storgard | Chief Medical Officer | USD 633.76K | 60 | 250.00K | 0.40% |
Doane Chilcoat | Chief Technology Officer | — | — | — | — |
Jim Kerr | Chief of Manufacturing & Product Development | — | — | — | — |
Julie D. Burgess | Chief Accounting Officer | — | — | — | — |
Aseem Z. Ansari | Co-Founder & Scientific Advisor | — | — | 100.00K | 0.16% |
Tadimeti S. Rao | Chief Scientific Officer | — | — | — | — |
Mustapha Parekh | General Counsel | — | — | — | — |
Chengzhi Zhang | Chief Chemist | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 7, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Jan 2, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
No open-market purchases or sales in the last 12 months.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | N/A | N/A3 analysts |
| Net Income | N/A | N/A | N/A | N/A3 analysts |
| EBIT | N/A | N/A | N/A | N/A3 analysts |
Analysis
Analysis will appear once historical growth or forward estimates are available for this company.
Competitors
Who does Design Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Competitors
Peer companies in the same sector
Questions
Management questions
Common questions about DSGN's management, answered from reported figures.
Who manages DSGN?
Design Therapeutics, Inc. (DSGN) lists 10 active executives. The top listed executive is Doane Chilcoat, Chief Technology Officer.
Are DSGN insiders buying or selling?
Recent insider activity shows net buying of $134.28M.
Continue the stock analysis
Jump to another research area for this company.